Panobinostat (LBH589)

Name: Panobinostat (LBH589)
Brand: Selleck Chemicals
SKU: S1030
Rating: 5 (216 reviews)

For research use only. Not for use in humans.

Catalog No.S1030 Synonyms: NVP-LBH589

216 publications

Panobinostat (LBH589) Chemical Structure

Molecular Weight(MW): 349.43

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Selleck's Panobinostat (LBH589) has been cited by 216 publications

Cancer Cell, 2019, 36(2):179-193

PubMed: 31378681 ( click the link to review the publication )

Cancer Cell, 2019, 36(5):528-544

PubMed: 31631026 ( click the link to review the publication )

Cell, 2019, 36(2):179-193

PubMed: 28162770 ( click the link to review the publication )

Cancer Cell, 2019, 35(5):782-797

PubMed: 31085178 ( click the link to review the publication )

Nat Immunol, 2019, 20(7):835-851

PubMed: 31160797 ( click the link to review the publication )

Nat Med, 2018, 24(11):1752-1761

PubMed: 30349086 ( click the link to review the publication )

Cell, 2018, 173(6):1413-1425

PubMed: 29754815 ( click the link to review the publication )

Nat Genet, 2018, 50(10):1442-1451

PubMed: 30224647 ( click the link to review the publication )

Cancer Discov, 2017, 7(12):1450-1463

PubMed: 28963352 ( click the link to review the publication )

Cancer Cell, 2017, 31(5):635-652

PubMed: 28434841 ( click the link to review the publication )

Cancer Cell, 2016, 29(3):311-323

PubMed: 26977882 ( click the link to review the publication )

Nat Med, 2015, 10.1038/nm.3855

PubMed: 25939062 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cancer Discov, 2015, 5(3):264-73

PubMed: 25542447 ( click the link to review the publication )

Cell, 2014, 159(5):1110-25

PubMed: 25416949 ( click the link to review the publication )

Nat Biotechnol, 2011, 29(3):255-65

PubMed: 21258344 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2020, 10.1007/s00280-019-04021-y

PubMed: 31894347 ( click the link to review the publication )

Cell Res, 2019, 29(4):286-304

PubMed: 30631154 ( click the link to review the publication )

Nat Commun, 2019, 10(1):3319

PubMed: 31346162 ( click the link to review the publication )

Clin Cancer Res, 2019, 10.1158/1078-0432

PubMed: 31227503 ( click the link to review the publication )

Leukemia, 2019, 10.1038/s41375-019-0525-6

PubMed: 31358854 ( click the link to review the publication )

Proc Natl Acad Sci U S A, 2019, 116(26):12986-12995

PubMed: 31182587 ( click the link to review the publication )

Neuro Oncol, 2019, 10.1093/neuonc/noz215

PubMed: 31711240 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(2):230-243

PubMed: 30563830 ( click the link to review the publication )
Cancer Res, 2019, 79(11):2947-2961

PubMed: 30987999 ( click the link to review the publication )

Haematologica, 2019, 10.3324/haematol.2018.211110

PubMed: 30846494 ( click the link to review the publication )

Clin Infect Dis, 2019, 10.1093/cid/ciz108

PubMed: 30753360 ( click the link to review the publication )

J Immunother Cancer, 2019, 7(1):33

PubMed: 30728070 ( click the link to review the publication )

Theranostics, 2019, 9(2):540-553

PubMed: 30809292 ( click the link to review the publication )

Cell Rep, 2019, 29(9):2783-2795

PubMed: 31775045 ( click the link to review the publication )

Elife, 2019, 10.7554/eLife.44306

PubMed: 31050342 ( click the link to review the publication )

Oncogene, 2019, 38(15):2690-2705

PubMed: 30538293 ( click the link to review the publication )

J Exp Clin Cancer Res, 2019, 38(1):185

PubMed: 31053152 ( click the link to review the publication )

Cancers (Basel), 2019, 11(10)

PubMed: 31561534 ( click the link to review the publication )

PLoS Pathog, 2019, 15(8):e1007991

PubMed: 31425551 ( click the link to review the publication )

Breast Cancer Res, 2019, 21(1):134

PubMed: 31801577 ( click the link to review the publication )

Acta Pharm Sin B, 2019, 9(5):937-951

PubMed: 31649844 ( click the link to review the publication )

Front Immunol, 2019, 9:3162

PubMed: 30723480 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(5):900-908

PubMed: 30824609 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(1):185-195

PubMed: 30301863 ( click the link to review the publication )

Mol Cancer Ther, 2019, 18(8):1439-1450

PubMed: 31142662 ( click the link to review the publication )

Biochim Biophys Acta Mol Basis Dis, 2019, 1865(6):1666-1676

PubMed: 30954557 ( click the link to review the publication )

J Biomed Nanotechnol, 2019, 15(5):979-992

PubMed: 30890229 ( click the link to review the publication )

Epigenetics, 2019, 10.1080/15592294.2019.1656156

PubMed: 31423932 ( click the link to review the publication )

AIDS, 2019, 33(2):199-209

PubMed: 30562171 ( click the link to review the publication )

Biomolecules, 2019, 9(5)

PubMed: 31083537 ( click the link to review the publication )

Mol Pharm, 2019, 16(5):1813-1826

PubMed: 30883132 ( click the link to review the publication )

J Cell Physiol, 2019, 234(10):18970-18984

PubMed: 30916359 ( click the link to review the publication )
Eur J Nutr, 2019, 10.1007/s00394-019-01925-6

PubMed: 30762097 ( click the link to review the publication )

J Virol, 2019, 93(24)

PubMed: 31578289 ( click the link to review the publication )

Antimicrob Agents Chemother, 2019, 63(2)

PubMed: 30455231 ( click the link to review the publication )

Epigenetics Chromatin, 2019, 12(1):18

PubMed: 30871586 ( click the link to review the publication )

Int J Mol Sci, 2019, 20(12)

PubMed: 31234549 ( click the link to review the publication )

J Biol Chem, 2019, 294(12):4437-4449

PubMed: 30670592 ( click the link to review the publication )

Apoptosis, 2019, 24(1-2):184-197

PubMed: 30498998 ( click the link to review the publication )

Mol Carcinog, 2019, 58(12):2230-2240

PubMed: 31478563 ( click the link to review the publication )

Mol Carcinog, 2019, 58(2):234-246

PubMed: 30303565 ( click the link to review the publication )

Virus Res, 2019, 269:197631

PubMed: 31136823 ( click the link to review the publication )

Mol Genet Genomic Med, 2019, 7(5):e613

PubMed: 30891950 ( click the link to review the publication )

Childs Nerv Syst, 2019, 35(5):823-831

PubMed: 30815722 ( click the link to review the publication )

J Nanobiotechnology, 2019, 17(1):69

PubMed: 31113488 ( click the link to review the publication )

J Virus Erad, 2019, 5(3):133-137

PubMed: 31700655 ( click the link to review the publication )

Nat Commun, 2018, 9(1):4866

PubMed: 30451831 ( click the link to review the publication )

Nat Commun, 2018, 9(1):764

PubMed: 29472538 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(16):3941-3954

PubMed: 29764852 ( click the link to review the publication )

Clin Cancer Res, 2018, 24(1):120-129.

PubMed: 29066507 ( click the link to review the publication )

Cancer Res, 2018, 78(5):1155-1168

PubMed: 29259009 ( click the link to review the publication )

Cancer Res, 2018, 78(14):4007-4021

PubMed: 29760046 ( click the link to review the publication )

Int J Cancer, 2018, 143(6):1388-1401

PubMed: 29633255 ( click the link to review the publication )

Oncogene, 2018, 37(6):722-731

PubMed: 29059175 ( click the link to review the publication )

Cancer Lett, 2018, 417:152-160

PubMed: 29306016 ( click the link to review the publication )

Sci Signal, 2018, 11(557)

PubMed: 30459282 ( click the link to review the publication )
EBioMedicine, 2018, 28:80-89

PubMed: 29396295 ( click the link to review the publication )

Cell Death Dis, 2018, 9(10):944

PubMed: 30237504 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(12):2767-2779

PubMed: 30232145 ( click the link to review the publication )

Mol Cancer Ther, 2018, 17(8):1705-1716

PubMed: 29748211 ( click the link to review the publication )

Cell Oncol (Dordr), 2018, 41(2):201-212

PubMed: 29260509 ( click the link to review the publication )

J Immunol, 2018, 201(3):1086-1096

PubMed: 29914885 ( click the link to review the publication )

J Virol, 2018, 92(13)

PubMed: 29643247 ( click the link to review the publication )

Int J Mol Sci, 2018, 19(8)

PubMed: 30081552 ( click the link to review the publication )

Sci Rep, 2018, 8(1):9472

PubMed: 29930256 ( click the link to review the publication )

Biomed Pharmacother, 2018, 100:509-520

PubMed: 29494986 ( click the link to review the publication )

J Cell Biochem, 2018, 119(5):4193-4204

PubMed: 29274289 ( click the link to review the publication )

Retrovirology, 2018, 15(1):36

PubMed: 29751762 ( click the link to review the publication )

J Ethnopharmacol, 2018, 211:267-277

PubMed: 28970153 ( click the link to review the publication )

Exp Cell Res, 2018, 363(2):196-207

PubMed: 29317217 ( click the link to review the publication )

PLoS One, 2018, 13(11):e0207915

PubMed: 30481203 ( click the link to review the publication )

PLoS One, 2018, 13(12):e0208147

PubMed: 30592723 ( click the link to review the publication )

Dis Markers, 2018, 2018:3810108

PubMed: 30647797 ( click the link to review the publication )

Cell Biochem Funct, 2018, 36(8):398-407

PubMed: 30484863 ( click the link to review the publication )

Anticancer Drugs, 2018, 29(1):61-74

PubMed: 29049036 ( click the link to review the publication )

Oncotarget, 2018, 9(92):36530-36541

PubMed: 30559935 ( click the link to review the publication )

Oncotarget, 2018, 9(5):6450-6462

PubMed: 29464084 ( click the link to review the publication )

F1000Res, 2018, 7:1906

PubMed: 30881689 ( click the link to review the publication )

Oncotarget, 2018, 9(47):28586-28598

PubMed: 29983882 ( click the link to review the publication )

Int J Radiat Oncol Biol Phys, 2018, 100(1):174-187

PubMed: 29107335 ( click the link to review the publication )
Nat Commun, 2017, 8(1):728

PubMed: 28959017 ( click the link to review the publication )

Cancer Res, 2017, 77(11):3027-3039

PubMed: 28363998 ( click the link to review the publication )

Int J Cancer, 2017, 141(9):1921-1931

PubMed: 28710768 ( click the link to review the publication )

Plant Physiol, 2017, 175(4):1760-1773

PubMed: 29018096 ( click the link to review the publication )

Arch Toxicol, 2017, 91(5):2191-2208

PubMed: 27807597 ( click the link to review the publication )

Arch Toxicol, 2017, 91(1):365-391

PubMed: 27015953 ( click the link to review the publication )

Arch Toxicol, 2017, 91(2):839-864

PubMed: 27188386 ( click the link to review the publication )

Mol Cancer Ther, 2017, 16(2):285-299

PubMed: 27980108 ( click the link to review the publication )

Br J Haematol, 2017, 178(5):728-738

PubMed: 28480959 ( click the link to review the publication )

Epigenetics, 2017, 12(2):105-112

PubMed: 27935420 ( click the link to review the publication )

Int J Nanomedicine, 2017, 12:1385-1399

PubMed: 28260886 ( click the link to review the publication )

J Biol Chem, 2017, 292(9):3683-3691

PubMed: 28087699 ( click the link to review the publication )

J Pharmacol Exp Ther, 2017, 363(2):211-220

PubMed: 28860353 ( click the link to review the publication )

Mol Biol Cell, 2017, 28(26):3756-3772

PubMed: 29074567 ( click the link to review the publication )

Exp Cell Res, 2017, 350(1):218-225

PubMed: 27914787 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2017, 7(1):42-50

PubMed: 28107750 ( click the link to review the publication )

PLoS One, 2017, 12(1):e0169485

PubMed: 28052119 ( click the link to review the publication )

Horm Cancer, 2017, 8(4):257-267

PubMed: 28516379 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:11-22

PubMed: 27761810 ( click the link to review the publication )

Blood Adv, 2017, 1(19):1575-1583

PubMed: 29296798 ( click the link to review the publication )

Genom Data, 2017, 12:14-16

PubMed: 28239551 ( click the link to review the publication )

JCI Insight, 2017, 2(1):e85811

PubMed: 28097226 ( click the link to review the publication )

JCI Insight, 2017, 2(6):e90196

PubMed: 28352655 ( click the link to review the publication )

Oncotarget, 2017, 9(3):3908-3921

PubMed: 29423093 ( click the link to review the publication )
Oncotarget, 2017, 8(18):30019-30029

PubMed: 28415789 ( click the link to review the publication )

Oncotarget, 2017, 8(34):56747-56757

PubMed: 28915627 ( click the link to review the publication )

Oncotarget, 2017, 8(44):77254-77267

PubMed: 29100385 ( click the link to review the publication )

Oncotarget, 2017, 8(55):94569-94579

PubMed: 29212250 ( click the link to review the publication )

Methods Mol Biol, 2017, 1510:127-148

PubMed: 27761818 ( click the link to review the publication )

Blood, 2016, 127(10):1325-35

PubMed: 26668133 ( click the link to review the publication )

Nucleic Acids Res, 2016, 45(3):1159-1176

PubMed: 28180300 ( click the link to review the publication )

EMBO Mol Med, 2016, 8(2):117-38

PubMed: 26681773 ( click the link to review the publication )

Clin Cancer Res, 2016, 22(10):2534-44

PubMed: 26733615 ( click the link to review the publication )

Int J Cancer, 2016, 139(1):194-204

PubMed: 26914605 ( click the link to review the publication )

Oncogene, 2016, 35(46):6026-6037

PubMed: 27157610 ( click the link to review the publication )

Mol Oncol, 2016, 10(5):735-750

PubMed: 26775640 ( click the link to review the publication )

Mol Ther Methods Clin Dev, 2016, 3:16003

PubMed: 27626039 ( click the link to review the publication )

J Org Chem, 2016, 81(22):11324-11334

PubMed: 27768313 ( click the link to review the publication )

Mol Pharm, 2016, 13(11):3724-3735

PubMed: 27653969 ( click the link to review the publication )

Sci Rep, 2016, 6:38407

PubMed: 27910927 ( click the link to review the publication )

J Biol Chem, 2016, 291(16):8745-55

PubMed: 26912657 ( click the link to review the publication )

Biomed Pharmacother, 2016, 84:1393-1405

PubMed: 27802904 ( click the link to review the publication )

Retrovirology, 2016, 13(1):36

PubMed: 27206407 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2016, 142(11):2263-73

PubMed: 27576506 ( click the link to review the publication )

Am J Transl Res, 2016, 8(9):3893-3902

PubMed: 27725868 ( click the link to review the publication )

PLoS One, 2016, 11(2):e0148912

PubMed: 26859414 ( click the link to review the publication )

Leuk Lymphoma, 2016, 57(11):2644-52

PubMed: 26980288 ( click the link to review the publication )

JCI Insight, 2016, 1(5):e85061

PubMed: 27699258 ( click the link to review the publication )
Ann Rheum Dis, 2015, 10.1136/annrheumdis-2014-206258

PubMed: 25589513 ( click the link to review the publication )

Biomaterials, 2015, 73:110-9

PubMed: 26406451 ( click the link to review the publication )

Blood Cancer J, 2015, 5:e312

PubMed: 25978432 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: 25490700 ( click the link to review the publication )

J Med Chem, 2015, 58(2):785-800

PubMed: ( click the link to review the publication )

Arch Toxicol, 2015, 89(9):1599-618

PubMed: 26272509 ( click the link to review the publication )

Mol Oncol, 2015, 9(7):1447-1457

PubMed: 25957812 ( click the link to review the publication )

Mol Pharm, 2015, 12(7):2469-76

PubMed: 26030093 ( click the link to review the publication )

Sci Rep, 2015, 5:16445

PubMed: 26563568 ( click the link to review the publication )

Am J Physiol Lung Cell Mol Physiol, 2015, 309(12):L1410-9

PubMed: 26498249 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: 25540204 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 10.1074.jbc.M114.624361

PubMed: 25737447 ( click the link to review the publication )

J Biol Chem, 2015, 290(49):29478-92

PubMed: 26491017 ( click the link to review the publication )

J Biol Chem, 2015, 290(8):5028-40

PubMed: ( click the link to review the publication )

Cancer Biol Ther, 2015, 16(12):1784-93

PubMed: 26529495 ( click the link to review the publication )

Int J Parasitol Drugs Drug Resist, 2015, 5(3):117-26

PubMed: 26199860 ( click the link to review the publication )

PLoS One, 2015, 10(7):e0126566

PubMed: 26176219 ( click the link to review the publication )

PLoS One, 2015, 10(8):e0134426

PubMed: 26247786 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Pediatr Blood Cancer, 2015, 62(1):52-9

PubMed: 25308916 ( click the link to review the publication )

Exp Hematol, 2015, 43(6):448-61

PubMed: 25704054 ( click the link to review the publication )

Oncotarget, 2015, 6(19):17698-712

PubMed: 25989842 ( click the link to review the publication )

Western University, 2015, Western University

PubMed: ( click the link to review the publication )
Oncotarget, 2015, 6(25):21507-21

PubMed: 26087189 ( click the link to review the publication )

Oncotarget, 2015, 6(4):2088-100

PubMed: 25576920 ( click the link to review the publication )

Cancer Lett, 2014, 356(2 Pt B):656-68

PubMed: 25458954 ( click the link to review the publication )

PLoS Pathog, 2014, 10(4):e1004071

PubMed: 24722454 ( click the link to review the publication )

PLoS Pathog, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Anal Chem, 2014, 86(10):4642-7

PubMed: 24559101 ( click the link to review the publication )

Br J Cancer, 2014, 111(2):281-91

PubMed: 24946002 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1134

PubMed: 24651437 ( click the link to review the publication )

Br J Haematol, 2014, 167(5):639-50

PubMed: 25155625 ( click the link to review the publication )

J Immunol, 2014, 193(3):1333-43

PubMed: 24973453 ( click the link to review the publication )

Mol Carcinog, 2014, 53(9):722-35

PubMed: 23475695 ( click the link to review the publication )

BMC Cancer, 2014, 14:17

PubMed: 24418474 ( click the link to review the publication )

PLoS One, 2014, 9(11):e113341

PubMed: 25409334 ( click the link to review the publication )

PLoS One, 2014, 10(8):e1004287

PubMed: 25122219 ( click the link to review the publication )

Biochem Biophys Res Commun, 2014, 452(3):649-54

PubMed: 25193706 ( click the link to review the publication )

Curr Pharm Desigh, 2014, 20(11):1874-80

PubMed: 23888956 ( click the link to review the publication )

Head Neck, 2014, 10.1002/hed.23822

PubMed: 24986420 ( click the link to review the publication )

Nat Commun, 2013, 4:2735

PubMed: 24193185 ( click the link to review the publication )

Nucleic Acids Res, 2013, 41(12):6018-33

PubMed: 23625969 ( click the link to review the publication )

Leukemia, 2013, 27(6):1291-300

PubMed: 23411464 ( click the link to review the publication )

Cell Rep, 2013, 5(6):1679-89

PubMed: 24360956 ( click the link to review the publication )

Cancer Lett, 2013, 329(1):17-26

PubMed: 22995071 ( click the link to review the publication )

Breast Cancer Res, 2013, 15(4):R58

PubMed: 23879992 ( click the link to review the publication )

Cell Death Dis, 2013, 4:e655

PubMed: 23744355 ( click the link to review the publication )
Cell Death Dis, 2013, 4:e951

PubMed: 24309938 ( click the link to review the publication )

Br J Haematol, 2013, 162(4):559-62

PubMed: 23692150 ( click the link to review the publication )

Radiother Oncol, 2013, 108(3):429-33

PubMed: 23932191 ( click the link to review the publication )

AIDS, 2013, 27(18):2853-62

PubMed: 24189584 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2013, 139(9):1507-14

PubMed: 23824064 ( click the link to review the publication )

Cancer Chemother Pharmacol, 2013, 71(5):1325-34

PubMed: 23515752 ( click the link to review the publication )

PLoS One, 2013, 8(8):e74253

PubMed: 23991216 ( click the link to review the publication )

PLoS One, 2013, 8(11):e79106

PubMed: 24244429 ( click the link to review the publication )

PLoS One, 2013, 8(9):e76662

PubMed: 24098799 ( click the link to review the publication )

PLoS One, 2013, 8(7):e69992

PubMed: 23922886 ( click the link to review the publication )

J Thromb Thrombolysis, 2013, 35(2):185-92

PubMed: 23229086 ( click the link to review the publication )

Theriogenology, 2013, 80(6):630-5

PubMed: 23866857 ( click the link to review the publication )

Protein Expr Purif, 2013, 92(1):119-127

PubMed: 24056254 ( click the link to review the publication )

Genet Mol Res, 2013, 12(4):5405-13

PubMed: 24301913 ( click the link to review the publication )

The University of Western Ontario, 2013, CHAE YOUNG HAN

PubMed: ( click the link to review the publication )

Obstet Gynecol Int, 2013, 2013:828165

PubMed: 24381593 ( click the link to review the publication )

Blood, 2012, 119(6):1450-8

PubMed: 22144178 ( click the link to review the publication )

Clin Cancer Res, 2012, 18(2):408-16

PubMed: 22038994 ( click the link to review the publication )

Breast Cancer Res Tr, 2012, 131(3):777-89

PubMed: 21452019 ( click the link to review the publication )

J Neurooncol, 2012, 110(3):335-48

PubMed: 23054560 ( click the link to review the publication )

Acta Neuropathol, 2011, 122(5):637-50

PubMed: 21863243 ( click the link to review the publication )

PLoS One, 2011, 6(2):e17138

PubMed: 21359182 ( click the link to review the publication )

Sci Signal, 2010, 3(146):ra80

PubMed: 21045206 ( click the link to review the publication )

Biochem Bioph Res Co, 2010, 391(4):1748-51

PubMed: 20043870 ( click the link to review the publication )

Purity & Quality Control

Choose Selective HDAC Inhibitors

Biological Activity

Description

Panobinostat (LBH589) is a novel broad-spectrum HDAC inhibitor with IC50 of 5 nM in a cell-free assay. Phase 3.

Targets

HDAC (MOLT-4 cells) ^[1]	HDAC (Reh cells) ^[1]
5 nM	20 nM

In vitro

LBH589 induces apoptosis among MOLT-4 and Reh cells in a time- and dose-dependent manner. Moreover, LBH589 is more potent in MOLT-4 than in Reh cells. LBH589 markedly prevents the growth of both MOLT-4 and Reh cells in a dose-dependent manner at 48 hours. LBH589 treatment causes a 2- to 3-fold increase in the number of cells in the G2/M phase of the cell cycle compared with the control cells. LBH589 is associated with induction of histone H3K9 and histone H4K8 acetylation as well as decreasing levels of c-Myc expression in a dose-dependent manner. LBH589 treatment also increases the levels of p21 expression. LBH589 treatment also decreases the levels of c-Myc after an initial increase at the lowest dose (10 nM) in Reh cells. In addition, LBH589 gives rise to substantial increases in mRNA levels of proapoptosis and DNA repair genes. LBH589 induces increased levels of acetylated histone H3 and H4 at the GADD45G promoter. ^[1] Besides, LBH589 inhibits growth of non small cell lung cancer cell lines (such as human H1299, L55 and A549 with IC50 of 5 nM, 11 nM and 30 nM, respectively), mesothelioma (such as human OK-6 and Ok-5 with IC50 of 5 nM and 7 nM, respectively) and small cell lung cancer cell lines (such as human RG-1 and LD-T with IC50 of 4 nM and 5 nM, respectively). ^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
HT29	MmT5S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmHWNE0yOCEQvF2=	MkT5NE01KGR?		MYPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	NVnsdYxsOjZ5MEK3PFQ>
HepG2	MkLNS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NHHXNVgxNTFyIN88US=>	M1L3e\|AuPCCm		NWrXcZBRcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NETGXIszPjdyMke4OC=>
HT29	NGLKNodHfW6ldHnvckBCe3OjeR?=	MXu1NOKhdk1?	MXuyOE04OiCq		NIrscpRqdmS3Y3XkJIFkfGm4YYTpc44hd2ZiY3HzdIF{\SB\|IHHmeIVzKDR6wrDoxsA>	NVjjfVRWOjZ5MEK3PFQ>
HepG2	M{nuT2Z2dmO2aX;uJGF{e2G7	MmnjOVDDqG6P	NHP3fokzPC15MjDo		MVLpcoR2[2WmIHHjeIl3[XSrb36gc4Yh[2G\|cHHz[UA{KGGodHXyJFI1yqCqwrC=	M3nqbFI3PzB{N{i0
HCC827	NXHYU\|VET3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MYC1M\|cvPS9zMDDuUS=>	NHvV[oc4OsLiaB?=	NFXIZVBFVVOR	NVPHZVFl\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NHn2NVAzPjZ5NUS4OC=>
A549	MnXqS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NWjKO5J5OTBxMUWvNlAhdk1?	MVK3NuKhcA>?	MVPEUXNQ	NYLHVFg2\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NHe1elIzPjZ5NUS4OC=>
NCI-H460	NHPBVllIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MUmxNE8zOC9\|MDDuUS=>	M2fPRVczyqCq	M4fsUWROW09?	NYHTNnk6\W6qYX7j[ZMhfGinIHHueIlxem:uaX\ldoF1cX[nIHXm[oVkfCCxZjDldoxwfGmwaXK=	NFHkVlgzPjZ5NUS4OC=>
J89GFP	MmrtS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?			MnPmSG1UV8Li	MXLFR\|UxRTR7Lki1JOKyKDF{Lk[1JI5O	NI[x[JczPjV4M{W2PC=>
THP89GFP	MYHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?			NU\MZ5N1TE2VT9Mg	NG\x[I5GSzVyPUG5MlM1KMLzIE[uOFMhdk1?	NHO4SGQzPjV4M{W2PC=>
SK-NEP-1	NIrXSlNIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MWCwMlAy6oDVMUCuNEDPxE1?	M{Xae\|I1KGh?	NYTtWVlOTE2VT9Mg	Mk\JTWM2OD15Nj6zOEBvVQ>?	NV\SRnZ2OjZzN{[yNVk>
G401	NEfTU2NIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NYjKWZF4OC5yMfMAl\|ExNjBizszN	NXvCTm9JOjRiaB?=	NVPybZNZTE2VT9Mg	NEPpbJlKSzVyPUG0N{4xOiCwTR?=	MmTYNlYyPzZ{MUm=
SK-NEP-1	MXjD[YxtKF[rYXLpcIl1gSCDc4PhfS=>	NF3HS3c2OCCwTR?=	NF\VUWcy6oDVNDDk	NIP0OG5FVVORwrC=	MWHy[YR2[2W\|IHPlcIwhe3W{dnn2ZYwhcW5iYTD0bY1mKGSncHXu[IVvfCCvYX7u[ZI>	MoPKNlYyPzZ{MUm=
G401	MnHyR4VtdCCYaXHibYxqfHliQYPzZZk>	MnP6OVAhdk1?	NHrzRnQy6oDVNDDk	M1;OW2ROW00EoB?=	Mly0doVlfWOnczDj[YxtKHO3co\peoFtKGmwIHGgeIlu\SCmZYDlcoRmdnRibXHucoVz	MoHtNlYyPzZ{MUm=
SK-NEP-1	NFuz[HBCeG:ydH;zbZMhSXO\|YYm=	NUjkVFRLPTBxMUCwJI5O	M3HqbFI1KGh?	NUHHdFNMTE2VT9Mg	MmfobY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NUm1d4xEOjZzN{[yNVk>
G401	M4nTPGFxd3C2b4Ppd{BCe3OjeR?=	NX[5N4FLPTBxMUCwJI5O	MVyyOEBp	MVnEUXNQyqB?	MnnvbY5lfWOnczDj[YxtKGGyb4D0c5NqeyCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	NXG3enRLOjZzN{[yNVk>
SK-NEP-1	M4PGNWZ2dmO2aX;uJGF{e2G7	NVm4NpgxPTBxMUCwJI5O	NEWyeIwzPCCq	Moe0SG1UV8Li	M4DSXpNpd3e\|IITo[UBqdmS3Y4Tpc44hd2ZiRF7BJIZz[WevZX70ZZRqd25?	MlWxNlYyPzZ{MUm=
G401	M3rRXWZ2dmO2aX;uJGF{e2G7	NVT4Z2tSPTBxMUCwJI5O	Mm\YNlQhcA>?	MoezSG1UV8Li	Mkntd4hwf3NidHjlJIlv\HWldHnvckBw\iCGTlGg[pJi\22nboTheIlwdg>?	M3;W[\|I3OTd4MkG5
SK-NEP-1	NV;hTZdiTnWwY4Tpc44hSXO\|YYm=	MUO1NE8yODBibl2=	MojmNlQhcA>?	NEW2O\|RFVVORwrC=	M164Solv\HWlZYOgZ4VtdCCleXPs[UBlcXOxcnTlduKh	MoTVNlYyPzZ{MUm=
G401	NHvCcWJHfW6ldHnvckBCe3OjeR?=	MUm1NE8yODBibl2=	MoO0NlQhcA>?	NIDzXGdFVVORwrC=	MVfpcoR2[2W\|IHPlcIwh[3mlbHWg[Il{d3KmZYNCpC=>	NXviV5hZOjZzN{[yNVk>
RPMI 8226	MWTD[YxtKFO3co\peoFtKEG\|c3H5	MYCyM\|QwPiCwTR?=	NFjwNVk1QOLCiXi=		MWjpcoR2[2W\|IHGgd4lodmmoaXPhcpQh\GWlcnXhd4UhcW5idHjlJINmdGxiZ4Lve5Rp	NV7KRlZEOjZyMECyPVI>
OPM2	MnrKR4VtdCCVdYL2bZZidCCDc4PhfS=>	MlexNk81NzZibl2=	NUDIW3VsPDkkgJno		NIj3XHdqdmS3Y3XzJIEhe2mpbnnmbYNidnRiZHXjdoVie2ViaX6geIhmKGOnbHyg[5Jwf3Sq	MoH0NlYxODB{OUK=
U266	NHG3d3RE\WyuIGP1dpZqfmGuIFHzd4F6	Mk\INk81NzZibl2=	M2\DfVQ56oDLaB?=		MmPybY5lfWOnczDhJJNq\26rZnnjZY51KGSnY4LlZZNmKGmwIITo[UBk\WyuIHfyc5d1cA>?	MYOyOlAxODJ7Mh?=
H929	MVvD[YxtKFO3co\peoFtKEG\|c3H5	M{\m[FIwPC94IH7N	NWfEeWYyPDkkgJno		NXfMNlh3cW6mdXPld{BiKHOrZ37p[olk[W62IHTlZ5Jm[XOnIHnuJJRp\SClZXzsJIdzd3e2aB?=	NVvaVnlsOjZyMECyPVI>
RPMI 8226	M4rpVGFxd3C2b4Ppd{BCe3OjeR?=	NU\Td2V3POLCiX7N	NYnoRpB4OjRxNEigbC=>		MV;pcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGmwIHGgeIlu\S2mZYDlcoRmdnRibXHucoVz	Mnf6NlYxODB{OUK=
HCC827	MVrHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MVOxNEBvVQ>?	M3f5clQ5KGh?	NULPNmF7TE2VTx?=	NEDINpFmdmijbnPld{BkcXOybHH0bY4he2Wwc3n0bZZqfHoEoB?=	NX3HNWJvOjV7NES2NVc>
NCI-H23	Mn;LS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M1jae\|ExKG6P	NYTPNHc3PDhiaB?=	NWC0V3ZMTE2VTx?=	M33TTYVvcGGwY3XzJINqe3CuYYTpckB{\W6\|aYTpeol1gcLi	NWnpdZQ5OjV7NES2NVc>
AML3	NGHBcIdHfW6ldHnvckBCe3OjeR?=	MXmwMVEh\|ryP	NYrZTXVmOjUEoHi=		MoKxbY5lfWOnczDEUmEh\nKjZ33lcpRifGmxbtMgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	MVeyOVYyOjl2MR?=
ML-1	MonRSpVv[3Srb36gRZN{[Xl?	MmHCNE0yKM7:TR?=	MmnYNlTDqGh?		M{P1WIlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MoTMNlU3OTJ7NEG=
RPMI-8226vr10	MV3GeY5kfGmxbjDBd5NigQ>?	MlqxNE0yKM7:TR?=	M{P3RVI1yqCq		M4TNcYlv\HWlZYOgSG5CKG[{YXft[Y51[XSrb39CpIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	NYDFb49IOjV4MUK5OFE>
ML-1	MWTGeY5kfGmxbjDBd5NigQ>?	MUGxJO69VQ>?	NGXObo8zPMLiaB?=		NVO1UYVpcW6lcnXhd4V{KGOjc4Dhd4UuOyCjY4Tpeol1gSB2LX\vcIQ>	NEHQV5QzPTZzMkm0NS=>
RPMI-8226vr10	NHrUZnRHfW6ldHnvckBCe3OjeR?=	M2DBSFEh\|ryP	NHjv[owzPMLiaB?=		M1zNcolv[3KnYYPld{Bk[XOyYYPlMVMh[WO2aY\peJkhOi53LX\vcIQ>	Mn7UNlU3OTJ7NEG=
SK-N-BE (2)	NFTTN4RIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		M4CxN\|I16oDLaB?=		Ml\kTWM2OD1zMESuNQKBkcLz4pEJO{45KG6P	MXqyOVMxQDlzNh?=
SK-N-BE (2), PAN MK	MVjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		MVuyOQKBkWh?		M3ziUGlEPTB;MUC0MlDjiIoEsfMAjVcvQCCwTR?=	NFfQZ\|UzPTNyOEmxOi=>
SK-N-BE (2), MK PAN	M1O1XWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGfjUI4zPOLCiXi=		M{jFRWlEPTB;M{iyMlDjiIoEsfMAjVQ{NjJibl2=	NHv4NJEzPTNyOEmxOi=>
SK-N-AS	NULsVFZKT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NULRW2t[OjUkgJno		NEHUV\|NKSzVyPUO3MlHjiIoEsfMAjVIvPCCwTR?=	NI\3W3EzPTNyOEmxOi=>
SK-N-DZ	NVrvN2x6T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MmSzNlTjiImq		MoH6TWM2OD1zNz6x5qCKyrIkgJmwMlQhdk1?	NEPhN5UzPTNyOEmxOi=>
Caki-1	Mkm3S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NU[3VVlmOTBxMkWvOVAhdk1?	MmHGOFghcA>?		MknzbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhicnn0c45ifmm{	MUOyOVI4QTF7MR?=
ACHN	NYT1bIY1T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MknjNVAwOjVxNUCgcm0>	NYDpUGtlPDhiaB?=		NFjk[pFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDybZRwdmG4aYK=	MoHWNlUzPzlzOUG=
769-P	MoXlS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NYXDWphvOTBxMkWvOVAhdk1?	MU[0PEBp		NXH1OGhHcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	NXHOSYVuOjV{N{mxPVE>
786-O	M{XuWmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NELGPFMyOC9{NT:1NEBvVQ>?	MlzZOFghcA>?		NX\5eY5NcW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnIHTldIVv\GWwdDDtZY5v\XJic4nu[ZJocXO2aXPhcIx6KHerdHigdol1d26jdnny	MmWwNlUzPzlzOUG=
Caki-1	NIexd25CeG:ydH;zbZMhSXO\|YYm=	MWW1NEBvVQ>?	MV20PEBp		MUnpcoR2[2W\|IHPlcIwh[XCxcITvd4l{KGOxbXLpcoVlKHKrdH;uZZZqeg>?	MUGyOVI4QTF7MR?=
ACHN	MXnBdI9xfG:\|aYOgRZN{[Xl?	NWT4PFR6PTBibl2=	Mn7oOFghcA>?		NHe1coxqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NVXy[2ZkOjV{N{mxPVE>
769-P	MVvBdI9xfG:\|aYOgRZN{[Xl?	MoPSOVAhdk1?	M4nYOFQ5KGh?		NG\kb4VqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IHPvcYJqdmWmIILpeI9v[X[rch?=	NHHSWZYzPTJ5OUG5NS=>
786-O	MV7BdI9xfG:\|aYOgRZN{[Xl?	NFXaZYs2OCCwTR?=	M1npdVQ5KGh?		M1zRVYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNiY3;tZolv\WRicnn0c45ifmm{	NGjwWYQzPTJ5OUG5NS=>
Caki-1	NX\lPIJlT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M37UT\|I2NzVyIH7N	MYW0PEBp	M2T4XGROW09?	MlvqbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmKGSncHXu[IVvfCCvYX7u[ZIhe3mwZYLnbZN1cWOjbHz5JJdqfGhiYn;yeIV7d22rYh?=	NUjke2V5OjVzN{[zOVQ>
ACHN	NF3zSFdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEfqU3EzPS93MDDuUS=>	M4Lj[FQ5KGh?	Mn;tSG1UVw>?	NIXTVlVqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2ViZHXw[Y5l\W62IH3hco5meiC\|eX7ldodqe3SrY3HscJkhf2m2aDDic5J1\XqxbXni	M1PNS\|I2OTd4M{W0
769-P	MVzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkjRNlUwPTBibl2=	M{LHV\|Q5KGh?	MVTEUXNQ	M2DQ[olvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\SCmZYDlcoRmdnRibXHucoVzKHO7bnXy[4l{fGmlYXzsfUB4cXSqIHLvdpRmgm:vaXK=	NInYSGEzPTF5NkO1OC=>
Caki-1	NIXKNWtEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NWTxUoFCPTBibl2=	M1ztVFcuOTRiZB?=	MXrEUXNQ	MmrHd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	MWmyOVE4PjN3NB?=
ACHN	MYTDc4xwdnliRn;ycYF1cW:wIFHzd4F6	MWC1NEBvVQ>?	MUC3MVE1KGR?	NUnBenZlTE2VTx?=	MYjzeZBxemW\|c3XkJINwdG:weTDmc5Ju[XSrb36gd4lodmmoaXPhcpRtgSClb33ibY5m\CC5aYToJJdqfGhiYn;yeIV7d22rYjFCpC=>	MkDhNlUyPzZ\|NUS=
769-P	NE\yXnZEd2yxbomgSo9zdWG2aX;uJGF{e2G7	NVf1VoJtPTBibl2=	MWW3MVE1KGR?	MY\EUXNQ	MnrCd5VxeHKnc4Pl[EBkd2yxbomg[o9zdWG2aX;uJJNq\26rZnnjZY51dHliY3;tZolv\WRid3n0bEB4cXSqIHLvdpRmgm:vaXKgxsA>	M{ewSFI2OTd4M{W0
Caki-1	MYXBdI9xfG:\|aYOgRZN{[Xl?	NXjRNXZIPTBibl2=	MkLxOFghcA>?	M2nVZ2ROW09?	NWrJeI86cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	M2fqWVI2OTd4M{W0
ACHN	MX7BdI9xfG:\|aYOgRZN{[Xl?	MlTMOVAhdk1?	MUe0PEBp	Mn76SG1UVw>?	MVrpcoR2[2W\|IHPlcIwh[XCxcITvd4l{	MnzqNlUyPzZ\|NUS=
769-P	MoTCRZBweHSxc3nzJGF{e2G7	M4PaRVUxKG6P	Mo\POFghcA>?	Ml;ESG1UVw>?	MV;pcoR2[2W\|IHPlcIwh[XCxcITvd4l{	NFTnTmkzPTF5NkO1OC=>
MDA-MB-231	M3TDWm1wenCqb3zv[4lk[WxiQ4L5d5RidCCYaX;s[ZQhMEOYKTDBd5NigQ>?	MU[xNOKhdk1?	M{fvRlPDqGR?	Mmf1SG1UVw>?	NYL1UWV7[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	M4PmZ\|I1QDFyNEm3
BT-549	MlqyUY9zeGixbH;nbYNidCCFconzeIFtKF[rb3zleEApS1ZrIFHzd4F6	M3yxTlExyqCwTR?=	M2XB[\|PDqGR?	MWjEUXNQ	NYPKRWRY[Wy2ZYLzJINmdGxibX;ydIhwdG:pedMg	NGTUNZYzPDhzMES5Oy=>
MCF-7	NI\FSYNOd3KyaH;sc4dq[2GuIFPyfZN1[WxiVnnvcIV1KCiFVjmgRZN{[Xl?	M3vQNFExyqCwTR?=	MnjiN:Kh\A>?	NV3qfJdbTE2VTx?=	MWHhcJRmenNiY3XscEBud3KyaH;sc4d6yqB?	MmPtNlQ5OTB2OUe=
MCF-7	M4S2eWZ2dmO2aX;uJGF{e2G7	MoPtOU02OCCwTR?=	M3LIXVI1KGh?	M2nRPGROW09?	NXLieXhkemWmdXPl[EB1cGVibHX2[Ywhd2ZiZYjwdoV{e2mxbjDv[kBGWs7zLDDQVkBidmRiRn;4RVHDqA>?	MX:yOFM3PjRyNx?=
CTS	MXzBdI9xfG:\|aYOgRZN{[Xl?	NUTQWpdVOOLCk{SwJI5OyqB?	NUj6cGhNPDhiaB?=		Mn[4bY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NUTUVY5NOjR{NES0Nlk>
OCI-AML3	NE[2eplCeG:ydH;zbZMhSXO\|YYm=	Mkm1NQKBmzRyIH7NxsA>	NHS4d4E1QCCq		NWTxPY1TcW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	MknlNlQzPDR2Mkm=
U937	NFf2bmNCeG:ydH;zbZMhSXO\|YYm=	MVWw5qCUPDBibl5CpC=>	NHi1[Vc1QCCq		NFG2U\|VqdmS3Y3XzJIFxd3C2b4Ppd{BqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NWD2epJGOjR{NES0Nlk>
PC3	MmDoRZBweHSxc3nzJGF{e2G7	Ml;GNE0yODBibl2=	Mnn3NlQwPDhiaB?=		M3rKUolv\HWlZYOgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M1Tk[\|I1OTZ\|MkOw
PC3-AR	NEGxb\|FCeG:ydH;zbZMhSXO\|YYm=	MVqwMVExOCCwTR?=	NX\afll5OjRxNEigbC=>		NVjreVFmcW6mdXPld{BieG:ydH;zbZMhcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NWrTU3lmOjRzNkOyN\|A>
PC3	MXzHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVGzZog{OC1zMECgcm0>	MnjDNlQwPDhiaB?=		NEW2OVdqdmS3Y3XzJIFk[3WvdXzheIlwdiCxZjDzeYJIOSCyb4D1cIF1cW:w	MVGyOFE3OzJ\|MB?=
PC3-AR	M3nBUmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	Mn\YNE0yODBibl2=	M3\0TVI1NzR6IHi=		MXvpcoR2[2W\|IHPlcIwh[3mlbHWgZZJz\XO2IHnuJJRp\SCJMl2gdIhie2V?	MonkNlQyPjN{M{C=
PC3	MUTGeY5kfGmxbjDBd5NigQ>?	MlLmNE0yODBibl2=	MYeyOEBp		NU\G[pF7e3WycILld5NmeyCneIDy[ZN{cW:wIH;mJIFkfGm4YYTl[EBCXE1uIFHreEBidmRiRYLrNU8zKHC{b4TlbY4>	NIf5ZXUzPDF4M{KzNC=>
PC3-AR	MW\GeY5kfGmxbjDBd5NigQ>?	NWP2Xo9VOC1zMECgcm0>	NYnCZXZVOjRiaB?=		NGLt[3N{fXCycnXzd4V{KGW6cILld5Nqd25ib3[gZYN1cX[jdHXkJGFVVSxiQXv0JIFv\CCHcnuxM\|IheHKxdHXpci=>	NWHmZ3VUOjRzNkOyN\|A>
OS-RC-2	NVnYUHlWS2WubDDWbYFjcWyrdImgRZN{[Xl?	NWW3TnJrOC1zMECwJI5O	NXu4ZnR3OjRxNEivO\|IhcA>?	M3HKeWROW09?	Mo\U[IVkemWjc3XzJINmdGxidnnhZoltcXS7IHnuJIJwfGhidHnt[U0h[W6mIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	MoTTNlQyPDR5M{e=
OS-RC-2	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M{Pnd\|UxKG6P	NY[z[FZ2PDhiaB?=	NUTNT4NMTE2VTx?=	MoPYbY5lfWOnczDHNk9OKGG{cnXzeC=>	NGXJbpMzPDF2NEezOy=>
OS-RC-2	NGP5[4xCeG:ydH;zbZMhSXO\|YYm=	NEXORZM2OCCwTR?=	MYS0PEBp	MYLEUXNQ	M{PtZolv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	MkLGNlQyPDR5M{e=
SK-N-AS	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NFnKNWkx6oDVOECgcm0>	NXnHbIpWPDhiaB?=		M363dWlEPTB;MkeuOEBvVQ>?	NVnCW4NWOjRyOUi3PVk>
SK-N-DZ	MVvHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MkPuNQKBmzhyIH7N	M3HCXVQ5KGh?		MXzJR\|UxRTJzLkmgcm0>	MWSyOFA6QDd7OR?=
SK-N-SH	M{C2[mdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MYmw5qCUQDBibl2=	NVHKeYQ4PDhiaB?=		M4LGdWlEPTB;N{KuN{BvVQ>?	NEfVZZQzPDB7OEe5PS=>
SK-N-BE	MoLiS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NXnjbIk{OOLCk{iwJI5O	Mke4OFghcA>?		NWTOTJRDUUN3ME23OU41KG6P	MoDYNlQxQTh5OUm=
SK-N-AS	MnmzRZBweHSxc3nzJGF{e2G7	NXrybVBiOOLCk{iwJI5O	M{C0SVQ5KGh?		MV\wc5RmdnSueTDpcoR2[2WmIHHwc5B1d3OrczDpckBiKGSxc3Wt[IVx\W6mZX70JIZie2irb36=	NEGycWEzPDB7OEe5PS=>
SK-N-DZ	MkDSRZBweHSxc3nzJGF{e2G7	NUfudpNLOOLCk{iwJI5O	M4TwV\|Q5KGh?		NWHSfFBweG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	MknDNlQxQTh5OUm=
SK-N-SH	MWnBdI9xfG:\|aYOgRZN{[Xl?	NE\Db44x6oDVNECgcm0>	MXG0PEBp		NVfoVHhqeG:2ZX70cJkhcW6mdXPl[EBieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCoYYPobY9v	M4\hO\|I1ODl6N{m5
SK-N-BE	M1nBZmFxd3C2b4Ppd{BCe3OjeR?=	MVuw5qCUPDBibl2=	M3HvNlQ5KGh?		M3rrbpBwfGWwdHz5JIlv\HWlZXSgZZBweHSxc3nzJIlvKGFiZH;z[U1l\XCnbnTlcpQh\mG\|aHnvci=>	M3T3cVI1ODl6N{m5
SK-N-AS	NEX1cnNHfW6ldHnvckBCe3OjeR?=	Ml32NQKBmzhyIH7N	MXq0PEBp		NUPZV4h[cW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NE\HPJAzPDB7OEe5PS=>
SK-N-DZ	M4TRe2Z2dmO2aX;uJGF{e2G7	M2\mSFDjiJN6MDDuUS=>	NHz3N5o1QCCq		M3rodIlv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	M{LONFI1ODl6N{m5
SK-N-SH	NX7WbmRUTnWwY4Tpc44hSXO\|YYm=	NUPvNINKOOLCk{SwJI5O	NXXTfZA5PDhiaB?=		M3LNU4lv\HWlZYOgZUBld3OnLXTldIVv\GWwdDDjcIVifmGpZTDv[kBk[XOyYYPlJFMh[W6mIGDBVnA>	M4ThZlI1ODl6N{m5
SK-N-BE	MYLGeY5kfGmxbjDBd5NigQ>?	MVmw5qCUPDBibl2=	M1m1PFQ5KGh?		NV\TWlZUcW6mdXPld{BiKGSxc3Wt[IVx\W6mZX70JINt\WG4YXflJI9nKGOjc4Dhd4UhOyCjbnSgVGFTWA>?	NFrvTIUzPDB7OEe5PS=>
HCC-LM3	MV7Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	M2q5XlEuOTByMDDuUS=>	Mo[4NlQwPDhxN{KgbC=>	NHH4[opFVVOR	MonObY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYn;0bEB1cW2nLTDhcoQh\G:\|ZT3k[ZBmdmSnboSgcYFvdmW{	NIPYT20zPDB7M{m1Oi=>
HepG2	MlnzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NVrwRmFrOS1zMECwJI5O	NVK3XFlQOjRxNEivO\|IhcA>?	NIXZcZFFVVOR	M1rkOolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHLveIghfGmvZT2gZY5lKGSxc3Wt[IVx\W6mZX70JI1idm6nch?=	M3PpVlI1ODl\|OUW2
SMMC-7721	NVjS[3A5T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	NETzVYgyNTFyMECgcm0>	NUTF[YZYOjRxNEivO\|IhcA>?	Ml3uSG1UVw>?	NHrXc2dqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NWHaVo1TOjRyOUO5OVY>
HCC-LM3	NGnBSY1CeG:ydH;zbZMhSXO\|YYm=	M4rUbFUxKG6P	NES2SpM1QCCq	MULEUXNQ	NWfsfnVvcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	MmD0NlQxQTN7NU[=
HepG2	NXfTZot{SXCxcITvd4l{KEG\|c3H5	NFX6UZI2OCCwTR?=	MWC0PEBp	NEjoNpdFVVOR	NInNRmJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|IIPp[45q\mmlYX70cJkhcW5iYTDjZZNx[XOnLXTldIVv\GWwdDDtZY5v\XJiYomgZ4xm[X[jZ3Wgc4Yh[2G\|cHHz[ZMhOyxiODDhcoQhQQ>?	M2WzeFI1ODl\|OUW2
SMMC-7721	M{TRS2Fxd3C2b4Ppd{BCe3OjeR?=	MV61NEBvVQ>?	NGC5NmI1QCCq	MXXEUXNQ	NWfmbo1CcW6mdXPld{Bk\WyuIHHwc5B1d3OrczDzbYdvcW[rY3HueIx6KGmwIHGgZ4F{eGG\|ZT3k[ZBmdmSnboSgcYFvdmW{IHL5JINt\WG4YXflJI9nKGOjc4Dhd4V{KDNuIEigZY5lKDl?	MUWyOFA6Ozl3Nh?=
HCC-LM3	NHzvUGZHfW6ldHnvckBCe3OjeR?=	NXHBZlFlPTBxMUCwJI5O	NH3wVFgzPCCq	Mn\rSG1UVw>?	M4jaT4Rm[3KnYYPld{B1cGVibHX2[Yx{KG:oIICtV3RCXDNiYX7kJJAuSWu2wrC=	MkDhNlQxQTN7NU[=
HepG2	MXvGeY5kfGmxbjDBd5NigQ>?	NWTTO40{PTBxMUCwJI5O	NUnIXnJvOjRiaB?=	NHzRWlRFVVOR	NETHNJdl\WO{ZXHz[ZMhfGinIHzleoVteyCxZjDwMXNVSVR\|IHHu[EBxNUGtdNMg	MVOyOFA6Ozl3Nh?=
SMMC-7721	NELsb\|BHfW6ldHnvckBCe3OjeR?=	NYq2[4RKPTBxMUCwJI5O	MVeyOEBp	Mmf2SG1UVw>?	MnLk[IVkemWjc3XzJJRp\SCuZY\lcJMhd2ZicD3TWGFVOyCjbnSgdE1Cc3UEoB?=	NXW0SIpLOjRyOUO5OVY>
HCC-LM3	NW\FNWw5TnWwY4Tpc44hSXO\|YYm=	NInOcIU2OC9zMECgcm0>	MVOyOEBp	M1qx[GROW09?	M2TkboRwf26{ZXf1cIF1\XNiQnPsMZhNKGW6cILld5Nqd25?	NViwWZY1OjRyOUO5OVY>
HepG2	MnXaSpVv[3Srb36gRZN{[Xl?	MXO1NE8yODBibl2=	M1T4eFI1KGh?	NGSyXGVFVVOR	MWDkc5dvemWpdXzheIV{KEKlbD34UEBmgHC{ZYPzbY9v	NWrVPYZIOjRyOUO5OVY>
SMMC-7721	MmnqSpVv[3Srb36gRZN{[Xl?	NUW2R\|RqPTBxMUCwJI5O	M1jzNlI1KGh?	MlXISG1UVw>?	MlXU[I94dnKnZ4XsZZRmeyCEY3ytfGwh\XiycnXzd4lwdg>?	Mn\iNlQxQTN7NU[=
FaDu	MUjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	MlTrNVAx6oDHbl2=	NYnqenluQC9zMD:xNkBp		MmTS[Il{eGyjeXXkJIEhe2mpbnnmbYNidnRiYX7kJJBzd2yxbnfl[EBIOi:PIHHydoV{fCCjdDC4JIFv\CBzMvMAiYgheG:\|dDDy[Yxm[XOn	NGrFVYIzPDB{NkS4Ni=>
FaDu	MoLISpVv[3Srb36gRZN{[Xl?	M{K2bFExOOLChX7N	MXuyM\|QwQC9zMjDo		M1H1V4lv\HWlZXSgdFIyX2GoMT;DbZAyyqCneIDy[ZN{cW:w	NFTH[2ozPDB{NkS4Ni=>
PC-3	MlX6S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MXmwMVExKM7:TR?=	Mlr6NlQwPDhxN{KgbC=>		NYnxc4F[cW6qaXLpeJMh[2WubDDndo94fGhiaX6gZo91cCC2aX3lMUBidmRiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	M2XoZ\|I{QTlzMkG2
LNCaP	MlT0S5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	NUjFcYNKOC13IN88US=>	NGe2XGgzPC92OD:3NkBp		NHLUbYFqdmirYnn0d{Bk\WyuIHfyc5d1cCCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NGWzRmQzOzl7MUKxOi=>
RWPE-1	M4LYXGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	MViwMVIxKM7:TR?=	MmK2NlQwPDhxN{KgbC=>		MVPpcohq[mm2czDj[YxtKGe{b4f0bEBqdiCkb4ToJJRqdWVvIHHu[EBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M37JUVI{QTlzMkG2
Capan-1	NYe3RZNKTnWwY4Tpc44hSXO\|YYm=	MnnnNlUwPTBxMUCwJI5O	M1fMVFgwOjRxNEigbC=>	NX32[482TE2VTx?=	MXHkc5dvemWpdXzheIVlKFKxbjDtVm5CKGGwZDDwdo91\WmwIHX4dJJme3Orb36gZY5lKGSxd37zeJJm[W1ic3nncoFtcW6p	NHG0TIczOzl{Mki4Oi=>
L3.6pl	M1;TdWZ2dmO2aX;uJGF{e2G7	MYOyOU82OC9zMECgcm0>	MVW4M\|I1NzR6IHi=	NFK2fYZFVVOR	M3TGcYRwf26{ZXf1cIF1\WRiUn;uJI1TVkFiYX7kJJBzd3SnaX6g[ZhxemW\|c3nvckBidmRiZH;3cpN1emWjbTDzbYdv[Wyrbne=	NU\S[HdLOjN7MkK4PFY>
CFPAC-1	NX7YXHZyTnWwY4Tpc44hSXO\|YYm=	NVzhUXFIOjVxNUCvNVAxKG6P	NYrkc2NEQC9{ND:0PEBp	MmOzSG1UVw>?	NH;IWXdld3ewcnXneYxifGWmIGLvckBuWk6DIHHu[EBxem:2ZXnuJIV5eHKnc4Ppc44h[W6mIHTve45{fHKnYX2gd4lodmGuaX7n	Mli0NlM6OjJ6OE[=
Capan-1	NWDSUlMyT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4fOc\|I2NzVyL{GwNEBvVQ>?	NYO2dnpoPDhiaB?=	NFuzXHZFVVOR	NGPzT3Fz\WS3Y3XzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	NVLE[plvOjN7MkK4PFY>
L3.6pl	NUXi[FZjT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	M4njeVI2NzVyL{GwNEBvVQ>?	NV\tSXlxPDhiaB?=	MoT2SG1UVw>?	NXfjTYxCemWmdXPld{Bk\WyuIHfyc5d1cCCrbjDhJIRwe2VvZHXw[Y5l\W62IH3hco5meg>?	MkPZNlM6OjJ6OE[=
CFPAC-1	MmfVS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	M33OeFI2NzVyL{GwNEBvVQ>?	MnrSOFghcA>?	NIPIVHdFVVOR	M3jJWZJm\HWlZYOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NWm1WY1OOjN7MkK4PFY>
Capan-1	M2TveWFxd3C2b4Ppd{BCe3OjeR?=	Mlq1NlUwPTBxMUCwJI5O	MXm0PEBp	NH7VcGNFVVOR	Ml\QbY5lfWOnczDj[YxtKGe{b4f0bEBqdiCjIHTvd4Uu\GWyZX7k[Y51KG2jbn7ldi=>	NWnGOpI{OjN7MkK4PFY>
L3.6pl	MXLBdI9xfG:\|aYOgRZN{[Xl?	MmS1NlUwPTBxMUCwJI5O	NXHxbnUxPDhiaB?=	NY\qfoVYTE2VTx?=	MWXpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWKyN\|kzOjh6Nh?=
CFPAC-1	MYTBdI9xfG:\|aYOgRZN{[Xl?	M4fYcFI2NzVyL{GwNEBvVQ>?	NIHpW\|g1QCCq	NHj0dWdFVVOR	MVHpcoR2[2W\|IHPlcIwh\3Kxd4ToJIlvKGFiZH;z[U1l\XCnbnTlcpQhdWGwbnXy	MWOyN\|kzOjh6Nh?=
HN22	MXjHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NVPHWGs6OC1{MDDuUS=>	M4jERlI1NzR6IHi=	M2[5W2ROW09?	MXHpcohq[mm2czDj[YxtKH[rYXLpcIl1gSCrbjDic5RpKHSrbXWtJIFv\CCmb4PlMUBl\XCnbnTlcpQhdWGwbnXy	MVKyN\|g4PzJ\|NR?=
HSC4	NFvoWW1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NGnsN2IxNTJyIH7N	MlfkNlQwPDhiaB?=	NY\OeGh[TE2VTx?=	NYnBRZc{cW6qaXLpeJMh[2WubDD2bYFjcWyrdImgbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	M4T4XlI{QDd5MkO1
HN22	NXKzZmpWSXCxcITvd4l{KEG\|c3H5	NHHkVYUxNTJyIH7N	M{Pt[VQ5KGh?	MkTZSG1UVw>?	NVS1TWd[cW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	NEf6ToczOzh5N{KzOS=>
HSC4	MlezRZBweHSxc3nzJGF{e2G7	MV:wMVIxKG6P	MkTrOFghcA>?	MUPEUXNQ	NYPLTo1UcW6mdXPld{Bk\WyuIHHwc5B1d3Orcx?=	MYSyN\|g4PzJ\|NR?=
HN22	NGO1XIxIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	MmfTNE0zOCCwTR?=	M4PuWVQ5KGh?	MWLEUXNQ	NVf1PJhocW6mdXPld{BIOSCyaHHz[UBk\WyuIHP5Z4xmKGG{cnXzeOKh	M1XBT\|I{QDd5MkO1
HSC4	MV;Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NGnPPIcxNTJyIH7N	NXviOZBEPDhiaB?=	NGXGXnJFVVOR	MnHFbY5lfWOnczDHNUBxcGG\|ZTDj[YxtKGO7Y3zlJIFzemW\|dNMg	M2XENFI{QDd5MkO1
HN22	M3zkfGZ2dmO2aX;uJGF{e2G7	MoPLNE0zOCCwTR?=	MVS0PEBp	NVnLS5RjTE2VTx?=	MYnzeZBxemW\|c3XzJHNxOSCneIDy[ZN{cW:wwrC=	NHvLSokzOzh5N{KzOS=>
HSC4	NWTuW4IyTnWwY4Tpc44hSXO\|YYm=	MU[wMVIxKG6P	NVfDbFhsPDhiaB?=	Moj1SG1UVw>?	MYfzeZBxemW\|c3XzJHNxOSCneIDy[ZN{cW:wwrC=	M4q5flI{QDd5MkO1
Cal62	NGrsdVJIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				Moi0TWM2OD1\|MzFCtUA1KG6P	M3XDN\|I{QDJ2ME[0
Hth7	MnPMS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1ywPGlEPTB;MUWgxtEhOiCwTR?=	M{X2d\|I{QDJ2ME[0
Hth83	MnfES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWjJR\|UxRTN2INMxJFUhdk1?	M4j1UFI{QDJ2ME[0
C643	NX7Q[JJXT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				Ml\jTWM2OD15MTFCtUAyOCCwTR?=	NWrXXZN4OjN6MkSwOlQ>
SW1736	NF6wOG1Iem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M{T4SWlEPTB;M{WgxtEhQCCwTR?=	MVuyN\|gzPDB4NB?=
T241	NEjLcplIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MnjETWM2OD14NTFCtUA4KG6P	MkHhNlM5OjRyNkS=
T351	MmDES5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M1z6cmlEPTB;NUCgxtEhOTBibl2=	MmfNNlM5OjRyNkS=
BHP2-7	MoPhS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M37P[mlEPTB;M{egxtEhPiCwTR?=	NXvxPFBsOjN6MkSwOlQ>
T238	M{fNbWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MWjJR\|UxRTFuNUCwJOKyKDJyMDDuUS=>	NXf0ToFJOjN6MkSwOlQ>
HCT8	NWfFb3JHT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NYLCZ5ZpPzJiaB?=	MVTEUXNQ	NWHxNZN2UUN3ME2xNk466oDLwsJihKkyNjlibl2=	NE\IN4MzOzJ7OUO4PC=>
H630	NWS5RpBDT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		NFP1Wng4OiCq	M1:4PGROW09?	MXHJR\|UxRTF{LkVihKnDueLCiUOuNUBvVQ>?	MmDhNlMzQTl\|OEi=
cH630 5-FU-res	M3PTcmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NIDOZ4Q4OiCq	NHjzb3NFVVOR	MnPvTWM2OD1zNT615qCKyrIkgJmxMlIhdk1?	M3XUWlI{Ojl7M{i4
HCT116	MoXSS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?		M1\4dFczKGh?	M3q4[WROW09?	MlH1TWM2OD1zMD635qCKyrIkgJmyMlIhdk1?	NWTO[YpVOjN{OUmzPFg>
HCT116 p53−/−	NET3cJFIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		NEPWepY4OiCq	NWW1flJyTE2VTx?=	NEm2fJVKSzVyPUiuOwKBkcLz4pEJNU44KG6P	MnX5NlMzQTl\|OEi=
dHCT116 p21−/−	M4HSPGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NGn5bJE4OiCq	M1\RbmROW09?	NVfIS4w5UUN3ME21MlnjiIoEsfMAjVEvOyCwTR?=	M3nUSlI{Ojl7M{i4
HT29	M1HvVmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		Moe4O\|IhcA>?	MorxSG1UVw>?	MWDJR\|UxRTF4LkRihKnDueLCiUKuN{BvVQ>?	MlnmNlMzQTl\|OEi=
LoVo	M4fwXWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NY\HfHBJPzJiaB?=	MWfEUXNQ	NI\wOHBKSzVyPUWuNgKBkcLz4pEJNE43KG6P	NH2zSG8zOzJ7OUO4PC=>
RKO	MVHHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?		NHPOeJM4OiCq	MVnEUXNQ	M{\1Z2lEPTB;Nz655qCKyrIkgJmyMlIhdk1?	MV[yN\|I6QTN6OB?=
SW480	NX7hSnlST3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVW3NkBp	Mnn5SG1UVw>?	Mlf6TWM2OD1zNz615qCKyrIkgJmwMlghdk1?	MWSyN\|I6QTN6OB?=
eSW620	NG\DXoZIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=		MXS3NkBp	NFLZXXVFVVOR	MXfJR\|UxRTlwMfMAjeKy6oDLMj6xJI5O	MVKyN\|I6QTN6OB?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	DNMT1 / EZH2; PubMed: 19279403 Cancer Biol Ther Western blot of DNMT1 and EZH2 in K562 and LAMA84 following 24 hours treatment with the indicated doses of panobinostat (PS). The levels of β-actin served as the loading control. caspase-8 / cleaved caspase-8 / Sp1; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of caspase-8, cleaved caspase 8 and Sp1 were analyzed by Western blotting. c-Myc / IRF4; PubMed: 27738323 Oncotarget RPMI8226 cells were cultured for 24 hours in the absence or presence of panobinostat at the indicated concentrations. Then, the protein levels of cMyc and IRF4 were analyzed by Western blotting. Ac-H3 / cleaved caspase-3 / CCND1 / ID1 / ID2 / ID3 / ID4 / Synaptophysin / NeuroD1; PubMed: 28915627 Oncotarget Immunoblotting of whole cell lysates prepared from MB cells treated with panobinostat. The representative western blot result shows panobinostat clearly regulated acetyl-Histone H3 (Ac-H3), cleaved caspase-3, CCND1, IDs, synaptophysin and NeuroD1. RAD51 / BRCA1 / CHK1 / RPL13a; PubMed: 24244429 PLoS One CTS, OCI-AML3 or U937 AML cells were treated with variable concentrations of panobinostat for 48 h. Whole cell lysates were subjected to Western blotting to measure protein levels for BRCA1, CHK1, and RAD51 in the cells. H3K9AC / H3K18AC / H3K56AC / H3 / H4K8AC / H4K16AC / H4 / p21 / p27 / cleaved PARP; PubMed: 31071955 Int J Mol Sci Immunoblot analyses of histone acetylation (H3K9AC, H3K18AC, H3K56AC, H4K8AC and H4K16AC), cell cycle arrest (p27 and p27) and apoptotic-related protein (C-Caspase 3 and C-PARP) expression following various panobinostat treatments for 6 h and 24 h on K562 cells. H3, H4 and GAPDH immunoblots served as internal controls.	19279403 27738323 28915627 24244429 31071955
Immunofluorescence	Synaptophysin / NACM; PubMed: 28915627 Oncotarget Panobinostat treated cells are positive for (B) synaptophysin (red) and (C) NCAM (red). Scale bars, 50 μm. α-tubulin / Acetyl-α-tubulin; PubMed: 29983882 Oncotarget CLBL-1 cells were treated with 10 nM of panobinostat for 24 h and then microtubules were visualized by immunofluorescence labeling using antibodies against tubulin and acetylated tubulin (ac-tubulin) using the appropriate excitation and emission filters as described in the material and methods section. Representative microphotographs with tubulin and ac-tubulin labeling (green) and DAPI stained-nuclei (blue) at 100× magnification are shown. Scale bar, 5 μm. BiP; PubMed: 23544167 Transl Oncol Immunofluorescence analysis of BiP after 24 and 48 hours of treatment in HepG2 (upper panel) and Hep3B (lower panel) cells with 0.1 µM panobinostat and 10 nM thapsigargin, showing an increase and a different protein distribution in panobinostat-treated cells, comparable to 10 nM thapsigargin effect, used as a positive control. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. ATF4; PubMed: 23544167 Transl Oncol HepG2 (left panel) and Hep3B (right panel) cells were treated for 24 and 48 hours with 0.1 µM panobinostat and the immunofluorescence results show an increase of ATF4 and its nuclear localization in both cell lines. Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm. IRE1α / S724-IRE1α; PubMed: 23544167 Transl Oncol Analysis of IRE1α/XBP1 involvement. Immunofluorescence results of IRE1α and its phosphorylated form in HepG2 (A) and Hep3B (B) cell lines after 24 and 48 hours of treatment with 0.1 µM panobinostat. The results indicate that panobinostat induces an increase of both the total and the phosphorylated form of IRE1α and a spotted distribution of this protein (enlargement showed for phospho-IRE1α, B). Immunofluorescence analysis has been performed under identical settings. Nuclei were stained with Hoechst 33342. Magnification is x630, and scale bar represents 10 µm.	28915627 29983882 23544167
Growth inhibition assay	Cell viability; PubMed: 27738323 Oncotarget The indicated MM cell lines were cultured in triplicate in the absence or presence of panobinostat at the indicated concentrations. After culturing for 48 hours, cell viability was measured by a WST-8 cell proliferation assay. Results were expressed as the mean +/− SD.	27738323

In vivo

In lung cancer and mesothelioma animal models, LBH589 markedly decreases tumor growth by 62%. LBH589 is equally effective in immunocompetent and severe combined immunodeficien-cymice, suggesting that the inhibition of tumor growth by LBH589 is not due to direct immunologic effects. Daily LBH589, given i.p. at 20 mg/kg for 5 days per week, leading to an average decrease in growth of 70%. Compared with the corresponding control tumors, LBH589 leads to a 53% decrease for H526-derived tumors, an 81% decrease for BK-T-derived tumors, a 76% decrease for RG-1- derived tumors, and a 70% decrease for H69-derived tumors. In contrast to the lack of tumor regression notes in NSCLC and Meso-derived xenografted tumors that are treated under identical conditions and doses, LBH589 results in dramatic tumor regression in SCLC-derived tumors and RG-1-derived tumor. ^[2]

Protocol

Cell Research:^[1]

- Collapse

Cell lines: MOLT-4 cell lines and Reh (pre-B cells)
Concentrations: 50 nM
Incubation Time: 48 hours
Method: Untreated and LBH589-treated cells [human Ph- acute lymphoblastic leukemia MOLT-4 (T cells) and Reh (pre-B cells)] are stained with annexin V and propidium iodide using annexin V-FITC apoptosis detection kit I. The percentage of apoptotic and nonviable cells is determined by flow cytometry. At least 5 × 10⁴ cells are collected with a CyAn ADP Violet cytometer. Percentage apoptosis is calculated considering all the annexin V-positive plus the annexin V/PI-positive cells; percentage loss of cell viability is calculated considering all the annexin V-positive plus the PI-positive and the annexinV/PI-positive cells.
(Only for Reference)

Animal Research:^[2]

- Collapse

Animal Models: Severe combined immunodeficiency (SCID) mice with M30 (10⁷ cells) or A549 (5 × 10⁶ cells), H69 (2.5 × 10⁶ cells), BK-T (6.5 × 10⁶), H526 (10 × 10⁶), and RG1 (10 × 10⁶) cells
Formulation: Dextrose 5% in water
Dosages: 10 mg/kg, 20 mg/kg
Administration: Administered via i.p. injection
(Only for Reference)

References

- Collapse

Solubility (25°C)

In vitro	DMSO	69 mg/mL (197.46 mM)
	Water	Insoluble
	Ethanol	Insoluble
In vivo	Add solvents to the product individually and in order(Data is from Selleck tests instead of citations): 2% DMSO+48% PEG 300+2% Tween 80+ddH2O For best results, use promptly after mixing.	5mg/mL

* Please note that Selleck tests the solubility of all compounds in-house, and the actual solubility may differ slightly from published values. This is normal and is due to slight batch-to-batch variations.

Chemical Information Download Panobinostat (LBH589) SDF

Molecular Weight	349.43
Formula	C₂₁H₂₃N₃O₂
CAS No.	404950-80-7
Storage	3 years -20°C powder
Storage	2 years -80°C in solvent
Synonyms	NVP-LBH589
Smiles	CC1=C(CCNCC2=CC=C(\C=C\C(=O)NO)C=C2)C3=C([NH]1)C=CC=C3

Bio Calculators

Molarity Calculator

Calculate the mass, volume or concentration required for a solution. The Selleck molarity calculator is based on the following equation:

Mass (mg) = Concentration (mM) × Volume (mL) × Molecular Weight (g/mol)

*When preparing stock solutions, please always use the batch-specific molecular weight of the product found on the via label and MSDS / COA (available on product pages).

Dilution Calculator

Calculate the dilution required to prepare a stock solution. The Selleck dilution calculator is based on the following equation:

Concentration _(start) x Volume _(start) = Concentration _(final) x Volume _(final)

This equation is commonly abbreviated as: C1V1 = C2V2 ( Input Output )

* When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and MSDS / COA (available online).

The Serial Dilution Calculator Equation

Serial Dilutions
Concertration (start):
Dilution-folds:

Computed Result

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

Molecular Weight Calculator

Enter the chemical formula of a compound to calculate its molar mass and elemental composition:

Tip: Chemical formula is case sensitive. C10H16N2O2 c10h16n2o2

Instructions to calculate molar mass (molecular weight) of a chemical compound:

To calculate molar mass of a chemical compound, please enter its chemical formula and click 'Calculate'.

Definitions of molecular mass, molecular weight, molar mass and molar weight:

Molecular mass (molecular weight) is the mass of one molecule of a substance and is expressed in the unified atomic mass units (u). (1 u is equal to 1/12 the mass of one atom of carbon-12)
Molar mass (molar weight) is the mass of one mole of a substance and is expressed in g/mol.

Molarity Calculator

Clinical Trial Information (data from https://clinicaltrials.gov, updated on 2019-10-14)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03632317	Withdrawn	Drug: Panobinostat\|Drug: Everolimus	Glioma\|Diffuse Intrinsic Pontine Glioma	University of Michigan Rogel Cancer Center	October 2019	Phase 2
NCT03982134	Withdrawn	Drug: PDR001\|Drug: Panobinostat	Melanoma\|Non Small Cell Lung Cancer	Muhammad Furqan\|Novartis Pharmaceuticals\|University of Iowa	September 2019	Phase 1
NCT03515915	Recruiting	--	Patients With Recurrent or Refractory Multiple Myeloma	University Hospital Montpellier\|Poitiers University Hospital	April 23 2018	--

Tech Support

Answers to questions you may have can be found in the inhibitor handling instructions. Topics include how to prepare stock solutions, how to store inhibitors, and issues that need special attention for cell-based assays and animal experiments.

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

Frequently Asked Questions

Question 1:
How to reconstitute the compound for in vivo mice study?
Answer:
We recommend the vehicle is 2 % DMSO, 2 % Tween 80, 48%PEG300, 48% water. The compound is first dissolved in DMSO, then add Tween, PEG300, water in sequence.

HDAC Signaling Pathway Map

HDAC Inhibitors with Unique Features

Selective HDAC Inhibitor

RGFP966 : HDAC3-selective, IC50=80 nM.
Selective HDAC Inhibitor

Rocilinostat (ACY-1215) : HDAC5-selective, IC50=5 nM.
Most Potent HDAC Inhibitor

Quisinostat (JNJ-26481585) : HDAC1, IC50=0.11 nM; HDAC2, IC50=0.33 nM.
FDA-approved HDAC Inhibitor

Vorinostat (SAHA, MK0683) : Approved by FDA for cutaneous T cell lymphoma.
Newest HDAC Inhibitor

RG2833 (RGFP109) ^New : Brain-penetrant HDAC inhibitor with IC50 of 60 nM and 50 nM for HDAC1 and HDAC3, respectively.

Related HDAC Products

LMK-235 ^New

LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively.
CAY10603 ^New

CAY10603 is a potent and selective HDAC6 inhibitor with IC50 of 2 pM, >200-fold selectivity over other HDACs.
Domatinostat (4SC-202) ^New

4SC-202 is a selective class I HDAC inhibitor with IC50 of 1.20 μM, 1.12 μM, and 0.57 μM for HDAC1, HDAC2, and HDAC3, respectively. Also displays inhibitory activity against Lysine specific demethylase 1 (LSD1). Phase 1.
Vorinostat (SAHA)

Vorinostat (suberoylanilide hydroxamic acid, SAHA) is an HDAC inhibitor with IC50 of ~10 nM in a cell-free assay.
Entinostat (MS-275)

Entinostat (MS-275) strongly inhibits HDAC1 and HDAC3 with IC50 of 0.51 μM and 1.7 μM in cell-free assays, compared with HDACs 4, 6, 8, and 10. Phase 3.
Trichostatin A (TSA)

Trichostatin A (TSA) is an HDAC inhibitor with IC50 of ~1.8 nM in cell-free assays.
Romidepsin (FK228, Depsipeptide)

Romidepsin (FK228, depsipeptide) is a potent HDAC1 and HDAC2 inhibitor with IC50 of 36 nM and 47 nM in cell-free assays, respectively.

Features:More effective than other classical HDAC inhibitors such as TSA, TPX, and butyrate.
RGFP966

RGFP966 is an HDAC3 inhibitor with IC50 of 0.08 μM in cell-free assay, exhibits > 200-fold selectivity over other HDAC.
Tubastatin A

Tubastatin A is a potent and selective HDAC6 inhibitor with IC50 of 15 nM in a cell-free assay. It is selective against all the other isozymes (1000-fold) except HDAC8 (57-fold).
Mocetinostat (MGCD0103)

Mocetinostat (MGCD0103) is a potent HDAC inhibitor with most potency for HDAC1 with IC50 of 0.15 μM in a cell-free assay, 2- to 10- fold selectivity against HDAC2, 3, and 11, and no activity to HDAC4, 5, 6, 7, and 8. Phase 2.

Choose Your Country or Region

By Signaling Pathways

By product type

Panobinostat (LBH589)